Ani Pharmaceuticals Inc
ANIP- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001023024
In the last 90 days, Ani Pharmaceuticals Inc insiders filed 0 open-market purchases and 11 sales; 290 institutions reported holding it in 13F filings for Q3 2026, worth $1.66B in total; no superinvestor holds it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Nov 8, 2026, 10:37 PM ET
Revenue flow, FY2025
Where the revenue went in FY2025, from the income statement below. Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue; hover over a band or a bar for the exact amount.
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 12, 2026 | Jan 13, 2025 | Jan 8, 2024 | Mar 9, 2023 | Mar 15, 2022 |
| Revenue | $883.4M | $614.4M | $486.8M | $316.4M | $216.1M |
| Research and development | $51.7M | $44.6M | $34.3M | $22.3M | $11.4M |
| Selling, general and administrative | $317.7M | $249.6M | $161.7M | $124.0M | $84.3M |
| Operating income | $111.1M | $584.0K | $47.0M | -$35.3M | -$39.8M |
| Interest expense | $32.6M | $33.6M | $32.5M | $28.4M | $11.9M |
| Income tax | $17.5M | -$3.69M | $1.09M | -$14.8M | -$13.5M |
| Net income | $78.3M | -$18.5M | $18.8M | -$47.9M | -$42.6M |
| EPS, basic | $3.50 | $-1.04 | $0.86 | $-3.05 | $-3.40 |
| EPS, diluted | $3.32 | $-1.04 | $0.85 | $-3.05 | $-3.40 |
| Weighted shares, basic | 20.1M | 19.3M | 18.0M | 16.3M | 12.6M |
| Weighted shares, diluted | 21.2M | 19.3M | 18.2M | 16.3M | 12.6M |
| Margins and growth | |||||
| Operating margin | 12.6% | 0.1% | 9.6% | -11.2% | -18.4% |
| Net margin | 8.9% | -3.0% | 3.9% | -15.1% | -19.7% |
| Revenue growth, year over year | +43.8% | +26.2% | +53.9% | +46.4% | +3.7% |
| Net income growth, year over year | – | −198.6% | – | – | – |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024! | FY2023! | FY2022! | FY2021! |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 12, 2026 | Jan 13, 2025 | Jan 8, 2024 | Mar 9, 2023 | Mar 15, 2022 |
| Cash and equivalents | $285.6M | $144.9M | $221.1M | $48.2M | $100.3M |
| Accounts receivable | $281.1M | $221.7M | $162.1M | $165.4M | $128.5M |
| Inventory | $143.1M | $136.8M | $111.2M | $105.4M | $81.7M |
| Total current assets | $753.1M | $527.7M | $519.8M | $344.3M | $321.8M |
| Property, plant and equipment | $62.5M | $56.9M | $44.6M | $43.2M | $52.7M |
| Goodwill | $62.5M | $60.0M | $28.2M | $28.2M | $27.9M |
| Intangible assets | $479.5M | $541.8M | $209.0M | $251.6M | $294.1M |
| Total assets | $1.44B | $1.28B | $904.4M | $760.1M | $771.6M |
| Accounts payable | $62.6M | $45.7M | $36.7M | $29.3M | $23.0M |
| Short-term debt | $17.3M | $9.17M | $850.0K | $850.0K | $850.0K |
| Total current liabilities | $278.1M | $193.7M | $145.5M | $99.4M | $87.5M |
| Long-term debt | $291.8M | $309.1M | $284.8M | $285.7M | $286.5M |
| Total liabilities | $899.7M | $855.2M | $446.8M | $421.5M | $412.9M |
| Shareholders' equity | $540.7M | $403.7M | $432.7M | $313.7M | $333.9M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 12, 2026 | Jan 13, 2025 | Jan 8, 2024 | Mar 9, 2023 | Mar 15, 2022 |
| Operating cash flow | $185.2M | $64.0M | $119.0M | -$31.2M | $3.32M |
| Capital expenditures | $13.8M | $16.2M | $8.87M | $8.88M | $2.56M |
| Free cash flow | $171.4M | $47.8M | $110.1M | -$40.1M | $765.0K |
| Depreciation and amortization | $91.4M | $67.7M | $59.8M | $57.0M | $47.3M |
| Stock-based compensation | $37.9M | $29.3M | $20.7M | $14.6M | $10.5M |
| Dividends paid | $1.16M | $1.63M | $1.63M | $1.63M | $190.0K |
| Share buybacks | $12.2M | $11.0M | $4.99M | $1.96M | $890.0K |
| Investing cash flow | -$34.3M | -$404.7M | -$18.5M | -$15.7M | -$105.5M |
| Financing cash flow | -$9.94M | $264.9M | $67.4M | -$5.13M | $194.6M |
| Net change in cash | $140.7M | -$76.2M | $167.9M | – | – |
| Ratio | |||||
| Stock-based compensation, % of revenue | 4.3% | 4.8% | 4.2% | 4.6% | 4.9% |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
- A column marked ! failed an accounting identity (gross profit = revenue − cost of revenue, or assets = liabilities + equity, within 1%). Its numbers are shown as filed.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.